Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Conditions
Angina Pectoris | Coronary Artery Disease
What is the purpose of this trial?
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-PCI on the composite of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Gilead Sciences
- Dates:
- October 2011
- Last Updated:
- February 22, 2013
- Study HIC#:
- 1202009644
Clinicaltrials.gov ID: NCT01442038
